Literature DB >> 22094666

Depression drug disappoints.

Heidi Ledford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22094666     DOI： 10.1038/479278a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Drug safety crackdown revs up.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2010-08-05       Impact factor: 49.962

2.  Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine).

Authors:  R D Shytle; A A Silver; P R Sanberg
Journal:  Biol Psychiatry       Date:  2000-11-15       Impact factor: 13.382

3.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 4.  Nicotinic acetylcholine receptors as targets for antidepressants.

Authors:  R D Shytle; A A Silver; R J Lukas; M B Newman; D V Sheehan; P R Sanberg
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992
  4 in total
  7 in total

1.  Drug research: a plan for mental illness.

Authors:  Thomas R Insel; Barbara J Sahakian
Journal:  Nature       Date:  2012-03-14       Impact factor: 49.962

2.  Behavioral effects of nicotinic antagonist mecamylamine in a rat model of depression: prefrontal cortex level of BDNF protein and monoaminergic neurotransmitters.

Authors:  Sawsan Aboul-Fotouh
Journal:  Psychopharmacology (Berl)       Date:  2014-10-15       Impact factor: 4.530

Review 3.  Personalized medicine in major depressive disorder -- opportunities and pitfalls.

Authors:  Diane B Miller; James P O'Callaghan
Journal:  Metabolism       Date:  2012-09-26       Impact factor: 8.694

4.  Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.

Authors:  Oluseye K Onajole; J Brek Eaton; Ronald J Lukas; Dani Brunner; Lucinda Thiede; Barbara J Caldarone; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

5.  Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP).

Authors:  Patrick A Forcelli; Jill R Turner; Bridgin G Lee; Thao T Olson; Teresa Xie; Yingxian Xiao; Julie A Blendy; Kenneth J Kellar
Journal:  Neuropharmacology       Date:  2015-09-11       Impact factor: 5.250

Review 6.  Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.

Authors:  Marco Alessandrini; Mamoonah Chaudhry; Tyren M Dodgen; Michael S Pepper
Journal:  OMICS       Date:  2016-09-19

7.  Doubt about antidepressant-like effect.

Authors:  Qigang Zhou; Mengying Liu
Journal:  J Biomed Res       Date:  2012-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.